Home » Stocks » GNFT

Genfit S.A. (GNFT)

Stock Price: $4.35 USD 0.06 (1.40%)
Updated May 6, 2021 4:00 PM EDT - Market closed
Market Cap 203.48M
Revenue (ttm) 9.46M
Net Income (ttm) -123.44M
Shares Out 45.75M
EPS (ttm) -3.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $4.35
Previous Close $4.29
Change ($) 0.06
Change (%) 1.40%
Day's Open 4.34
Day's Range 4.24 - 4.36
Day's Volume 11,421
52-Week Range 3.63 - 22.18

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Lille, France; Cambridge, M A ; April 23 , 202 1 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseas...

1 week ago - GlobeNewsWire

Lille, France; Cambridge , M A ; April 2 2 , 202 1 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver dise...

2 weeks ago - GlobeNewsWire

GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update

1 month ago - GlobeNewsWire

Lille, France; Cambridge, MA; March 04, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, ...

2 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; February 26, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver disease...

2 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; February 22, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver disease...

2 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; February 10, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver disease...

2 months ago - GlobeNewsWire

Investors applauded the company's latest clinical results.

2 months ago - The Motley Fool

Genfit SA (NASDAQ: GNFT) shares shot up 150% in the after-hours trading today. What Happened: The France-based late-stage biopharmaceutical company said in the after-hours Tuesday that positive results ...

2 months ago - Benzinga

Lille, France; Cambridge, MA; February 09, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver disease...

2 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; January 28, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases...

3 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; January 27, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases...

3 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $GNFT #GNFT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Genfit SA

3 months ago - Business Wire

Lille, France; Cambridge, MA; January 13, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases...

3 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; January 11, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases...

3 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; January 8, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases ...

3 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; January 6, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases,...

4 months ago - GlobeNewsWire

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $GNFT #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Genfit SA American Depository Shares (NASDAQ: GNFT) filed a cl...

4 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $GNFT #classaction--The Law Offices of Frank R. Cruz Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors

4 months ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $GNFT #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors

4 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $GNFT #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors

4 months ago - Business Wire

Lille (France), Cambridge (Massachusetts, United States), December 7, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with ...

4 months ago - GlobeNewsWire

Lille (France), Cambridge (Massachusetts, United States), November 30, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with ...

5 months ago - GlobeNewsWire

Lille (France), Cambridge (Massachusetts, United States), November 23, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with ...

5 months ago - GlobeNewsWire

Lille (France), Cambridge (Massachusetts, United States), November 16, 2020 – GENFIT (Nasdaq and Euronext: GNFT a late-stage biopharmaceutical company dedicated to improving the lives of patients with m...

5 months ago - GlobeNewsWire

                   

5 months ago - GlobeNewsWire

GENFIT SA (GNFT) CEO Pascal Prigent on Q2 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Genfit SA (NASDAQ: GNFT) shot up on Monday after the company announced an agreement with Lab Corporation of America Holdings (NYSE: LH).

Other stocks mentioned: LH
7 months ago - 24/7 Wall Street

Lille, France; Cambridge, M.A.; September 24, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver dise...

7 months ago - GlobeNewsWire

Lille, France; Cambridge, M.A.; September 22, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver dise...

7 months ago - GlobeNewsWire

Lille, France; Cambridge, M.A.; August 26, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver disease...

8 months ago - GlobeNewsWire

Lille (France), Cambridge (Massachusetts, United States), August 05, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with m...

9 months ago - GlobeNewsWire

       

9 months ago - GlobeNewsWire

Genfit: Beaten Down But Not Dead

10 months ago - Seeking Alpha

Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

Genfit’s (NASDAQ:GNFT) loss may be a gain for other companies developing a treatment for one of the most rapidly growing health problems around the world, particularly Intercept Pharmaceuticals Inc.

11 months ago - GuruFocus

Non-alcoholic steatohepatitis biotechs are increasingly finding it difficult to make headway, and the lack of any approved therapy despite a slew of research is a testament to the challenge.

Other stocks mentioned: CBAY
11 months ago - Benzinga

One of the company's pipeline candidates flopped in a late-stage clinical trial.

11 months ago - The Motley Fool

Genfit stock lost half its value late Monday after the biotech company's promising hepatitis treatment failed in a Phase 3 test. The results are a boon for rival Intercept Pharmaceuticals.

11 months ago - Investors Business Daily

Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belongs to Inte...

Other stocks mentioned: BMY, ICPT, MDGL, NVS, PTCT, RHHBY
1 year ago - GuruFocus

Genfit: Near-Term Upside Of 650% As Read-Out Of The Year Approaches

1 year ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor in Genfit.

1 year ago - Zacks Investment Research

A French biopharmaceutical company hopes to become the first to gain approval of a drug to treat a widespread liver disease.

1 year ago - GuruFocus

Both companies aim to grab a piece of the multi-billion dollar market for treating patients with the liver disease NASH. So, which one should you buy?

Other stocks mentioned: ICPT
1 year ago - The Motley Fool

Genfit (NASDAQ: GNFT) on Monday afternoon announced a partnership with Terns Pharmaceuticals to develop and commercialize Elafibranor in Greater China.

1 year ago - Benzinga

Genfit expects to report interim results from its phase 3 NASH study, which is expected to be read out by the end of 2019.

1 year ago - Seeking Alpha

Genfit received Breakthrough Therapy Designation from the FDA for its Elafibranor to treat patients with primary biliary cholangitis.

2 years ago - Seeking Alpha

About GNFT

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-indu... [Read more...]

Industry
Biotechnology
IPO Date
Mar 27, 2019
CEO
Pascal Prigent
Country
France
Stock Exchange
NASDAQ
Ticker Symbol
GNFT
Full Company Profile

Financial Performance

In 2020, Genfit's revenue was 7.76 million, a decrease of -81.06% compared to the previous year's 40.96 million. Losses were -101.22 million, 55.4% more than in 2019.

Financial numbers in millions EUR.
Financial Statements